SynthesisBMC gastroenterology2026
Moderate alcohol consumption and clinical outcomes in MASLD: a systematic review and meta-analysis of longitudinal cohorts.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) remains controversial regarding the impact of moderate alcohol consumption on disease progression and clinical outcomes. This systematic review aimed to evaluate the effects of moderate alcohol intake (up to 30 g/day for men and 20 g/day for women) on the development and progression of Steatotic Liver Disease (SLD), including outcomes such as histopathological progression, hepatocellular carcinoma (HCC), cardiovascular disease, and mortality.
methodsThe review followed PRISMA guidelines and included longitudinal cohort studies identified through PubMed, Scopus, Web of Science, Embase, and LILACS. Nine studies were selected for qualitative analysis, and seven were included in the meta-analysis. Effect measures, Hazard Ratios (HR) and Odds Ratios (OR), were pooled using Cochrane RevMan, and study quality was assessed with the Newcastle-Ottawa Scale. PROSPERO: CRD420261277466.
resultsThe meta-analysis showed no statistically significant association between moderate alcohol consumption and fibrosis progression (HR: 1.63 [95% CI: 0.96-2.77]; OR: 1.44 [95% CI: 0.56-3.72]). However, a statistically significant protective association was observed for all-cause mortality (HR: 0.73 [95% CI: 0.62-0.86]). High heterogeneity was noted across studies (I
conclusionsEven moderate alcohol consumption may contribute to the progression of severe hepatic outcomes in SLD. These findings support clinical recommendations for total abstinence, particularly in patients with established fibrosis, to prevent progression to cirrhosis and hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.